CD38 and Miyoshi myopathy: To enhance antigen specificity based on MM patient expression profile, a panel of Fab’‐MORF1 conjugates targeting key MM surface markers (Fab’BCMA‐MORF1, Fab’SLAMF7‐MORF1, Fab’CD38‐MORF1) is developed, which pairs interchangeably with Fab’CD3‐MORF2 for T‐cell engagement.